Serum levels of MMP-3 and cathepsin K in patients with ankylosing spondylitis: Effect of TNFα antagonist therapy

Joint Bone Spine

Volumn 75, Issue 5, 2008, Pages 559-562

  Wendling, Daniel ^a   Cedoz, Jean Pierre ^a   Racadot, Evelyne ^b  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b ETABLISSEMENT FRANÇAIS DU SANG   (France)

Author keywords

Ankylosing spondylitis; Cathepsin K; IL 17; MMP 3; TNF alpha antagonists

Indexed keywords

ADALIMUMAB; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CATHEPSIN K; ETANERCEPT; HLA B27 ANTIGEN; INFLIXIMAB; INTERLEUKIN 17; OSTEOGENIC PROTEIN 1; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; CENTRIFUGATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC KIT; DISEASE ACTIVITY; DISEASE DURATION; DISEASE MARKER; DRUG EFFECT; DRUG EFFICACY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IMMUNOASSAY; MALE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANK SUM TEST;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; CATHEPSINS; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MATRIX METALLOPROTEINASE 3; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; SPONDYLITIS, ANKYLOSING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 53149102032     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2008.01.026     Document Type: Article

References (17)

1. François R.J., Neure L., Sieper J., et al. Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor α in two patients with early disease and transforming growth factor β in three more advanced cases. Ann Rheum Dis 65 (2006) 713-720
2. Lories R.J., Derese I., De Bari C., et al. Evidence for uncoupling of inflammation and joint remodeling in a mouse model of spondylarthritis. Arthritis Rheum 56 (2007) 489-497
3. Maksymowych W., Landewé R., Conner-Spady B., et al. Serum matrix metalloproteinase 3 is an independent predictor of structural damage progression in patients with ankylosing spondylitis. Arthritis Rheum 56 (2007) 1846-1853
4. Chen C.H., Lin K.C., Yu D.T., et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in ankylosing spondylitis: MMP-3 is a reproducibly sensitive and specific biomarker of disease activity. Rheumatology (Oxford) 45 (2006) 414-420
5. El Maghraoui A. Osteoporosis and ankylosing spondylitis. Joint Bone Spine 71 (2004) 291-295
6. Wendling D. Bone loss in ankylosing spondylitis: can we put the puzzle together?. J Rheumatol 32 (2005) 1184-1185
7. Yasuda Y., Kaleta J., and Bromme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv Drug Deliv Rev 57 (2005) 973-993
8. Morko J., Kiviranta R., Joronen K., et al. Spontaneous development of synovitis and cartilage degeneration in transgenic mice overexpressing cathepsin K. Arthritis Rheum 52 (2005) 3713-3717
9. Fujisaki K., Tanabe N., Suzuki N., et al. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Life Sci 80 (2007) 1311-1318
10. Wendling D., Cedoz J.P., Racadot E., et al. Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. Joint Bone Spine 74 (2007) 304-305
11. van der Linden S., Valkenburg H.A., and Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27 (1984) 361-368
12. Claudepierre P., Sibilia J., Goupille P., et al. Evaluation of a French version of the Bath Ankylosing Spondylitis Disease Activity Index in patients with spondyloarthropathy. J Rheumatol 24 (1997) 1954-1958
13. Ribbens C., Martin Y.P.M., Franchimont N., et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. Ann Rheum Dis 61 (2002) 161-166
14. Vandooren B., Kruithof E., Yu D.T., et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. Arthritis Rheum 50 (2004) 2942-2953
15. Yang C., Gu J., Rihl M., et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. Arthritis Rheum 15 51 (2004) 691-699
16. Skoumal M., Haberhauer G., Kolarz G., et al. Serum cathepsin K levels of patients with longstanding rheumatoid arthritis: correlation with radiological destruction. Arthritis Res Ther 7 (2005) R65-R70
17. Woo J.H., Lee H.J., Sung I.H., et al. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 34 (2007) 1753-1759